Scarica l'app Stockscreener
76.92
3.26%
-2.59
Dopo l'orario di chiusura:
76.94
0.02
+0.03%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HALO Giù?
Forum
Previsione
Precedente Chiudi:
$79.51
Aprire:
$79.31
Volume 24 ore:
2.22M
Relative Volume:
1.00
Capitalizzazione di mercato:
$9.05B
Reddito:
$947.36M
Utile/perdita netta:
$392.47M
Rapporto P/E:
25.47
EPS:
3.02
Flusso di cassa netto:
$392.71M
1 W Prestazione:
-1.91%
1M Prestazione:
+6.21%
6M Prestazione:
+20.11%
1 anno Prestazione:
+32.37%
Intervallo 1D:
$76.10
$79.53
Intervallo di 1 settimana:
$76.10
$82.22
Portata 52W:
$47.50
$82.22
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Nome
Halozyme Therapeutics Inc
Settore
Industria
Telefono
(858) 794-8889
Indirizzo
12390 EL CAMINO REAL, SAN DIEGO, CA
Compare HALO vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
76.92 | 9.35B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-04 | Downgrade | Goldman | Neutral → Sell |
| 2025-10-14 | Aggiornamento | Leerink Partners | Underperform → Market Perform |
| 2025-08-06 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-10 | Ripresa | Goldman | Neutral |
| 2025-05-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Downgrade | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-06-07 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | Iniziato | TD Cowen | Outperform |
| 2023-07-24 | Downgrade | Goldman | Buy → Neutral |
| 2023-07-24 | Iniziato | H.C. Wainwright | Buy |
| 2023-05-10 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Ripresa | Berenberg | Buy |
| 2023-03-16 | Downgrade | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | Ripresa | Morgan Stanley | Overweight |
| 2022-11-28 | Iniziato | Wells Fargo | Overweight |
| 2022-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2021-06-14 | Iniziato | Evercore ISI | Outperform |
| 2021-05-17 | Iniziato | SVB Leerink | Outperform |
| 2021-05-11 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | Reiterato | The Benchmark Company | Buy |
| 2020-12-17 | Iniziato | Berenberg | Buy |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-07-01 | Iniziato | The Benchmark Company | Buy |
| 2020-02-05 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | Iniziato | Goldman | Buy |
| 2019-11-05 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2018-10-19 | Ripresa | Piper Jaffray | Neutral |
| 2018-05-11 | Downgrade | Barclays | Equal Weight → Underweight |
| 2018-01-24 | Iniziato | Goldman | Neutral |
| 2017-10-16 | Reiterato | Piper Jaffray | Overweight |
| 2017-01-06 | Downgrade | Citigroup | Buy → Neutral |
| 2016-11-03 | Iniziato | Deutsche Bank | Buy |
| 2015-12-04 | Iniziato | Wells Fargo | Outperform |
| 2015-11-18 | Iniziato | Citigroup | Buy |
| 2015-09-22 | Iniziato | Barclays | Overweight |
| 2015-06-22 | Reiterato | JP Morgan | Overweight |
| 2015-03-03 | Reiterato | UBS | Buy |
| 2015-02-18 | Reiterato | MLV & Co | Buy |
| 2015-01-08 | Reiterato | MLV & Co | Buy |
Mostra tutto
Halozyme Therapeutics Inc Borsa (HALO) Ultime notizie
Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results - The Malaysian Reserve
Halozyme Therapeutics (HALO) to Report Q4 Results: Wall Street Expects Earnings Growth - Finviz
Biotech: Halozyme CEO explains what it looks for in M&A targets - Yahoo! Finance Canada
Profund Advisors LLC Trims Stock Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (HALO) to Release Earnings on Tuesday - MarketBeat
Halozyme Expecting Decade of Growth - San Diego Business Journal
New York State Common Retirement Fund Sells 3,399,839 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Renaissance Group LLC Invests $35.11 Million in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Assessing Halozyme Therapeutics (HALO) Valuation After Raised 2025 And 2026 Revenue Guidance - Sahm
Halozyme Therapeutics stock hits all-time high at 79.99 USD By Investing.com - Investing.com Nigeria
Halozyme Therapeutics (NASDAQ:HALO) Hits New 12-Month HighTime to Buy? - MarketBeat
Halozyme Therapeutics stock hits all-time high at 79.99 USD - Investing.com
A Look At Halozyme Therapeutics (HALO) Valuation After Raised 2025 And 2026 Revenue Guidance - Yahoo Finance
Halozyme Therapeutics, Inc. $HALO Shares Acquired by Thrivent Financial for Lutherans - MarketBeat
Helen Torley Sells 20,000 Shares of Halozyme Therapeutics (NASDAQ:HALO) Stock - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) CEO Sells 10,000 Shares - MarketBeat
Halozyme, Other Hot Medical Plays Lead 22 Stocks Onto Best Stock Lists Like IBD 50, IPO Leaders - Investor's Business Daily
Halozyme’s Drug-Delivery Royalties Are Driving A Rerating Case - Finimize
BI Asset Management Fondsmaeglerselskab A S Sells 155,995 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Hantz Financial Services Inc. Has $7.18 Million Stock Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
2 Under-the-Radar Biotech Stocks Set to Boom in 2026 - AOL.com
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term - Yahoo Finance
Zacks Research Has Positive Outlook of HALO FY2025 Earnings - MarketBeat
Benchmark maintains Buy rating on Halozyme stock amid raised guidance By Investing.com - Investing.com Canada
Q1 EPS Estimate for Halozyme Therapeutics Raised by Analyst - MarketBeat
Halozyme Therapeutics (HALO) Is Up 6.6% After Lifting Guidance And Expanding ENHANZE Beyond Oncology - Sahm
Strs Ohio Sells 25,069 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics: Key Acquisitions To Help Drive Long-Term Growth - Seeking Alpha
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: Uncovering A 8.77% Upside Potential - DirectorsTalk Interviews
(HALO) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Why This Stock Of The Day Is Story Of 'Layering And Duration' - Investor's Business Daily
Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report? - Finviz
Merck gains U.S. patent office support in Keytruda dispute - MSN
Halozyme Therapeutics, Inc. $HALO Shares Sold by Y Intercept Hong Kong Ltd - MarketBeat
What Halozyme Therapeutics (HALO)'s Upgraded Revenue Outlook and ENHANZE Acquisitions Strategy Means For Shareholders - Yahoo Finance
Is Halozyme Therapeutics (HALO) Still Attractive After Recent Drug Delivery Partnership-Driven Gains - Sahm
AlphaQuest LLC Acquires 34,011 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) Raised to Strong-Buy at Wall Street Zen - MarketBeat
Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Setup Watch: Is Halozyme Therapeutics Inc forming a breakout patternDip Buying & AI Optimized Trading Strategy Guides - baoquankhu1.vn
If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now - Yahoo Finance
Q4 EPS Forecast for Halozyme Therapeutics Lifted by Analyst - MarketBeat
Great Lakes Advisors LLC Sells 14,747 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
A Look At Halozyme Therapeutics (HALO) Valuation After Raised Guidance And Drug Delivery Acquisitions - Sahm
H.C. Wainwright Sees Strength in Halozyme Therapeutics' ENHANZE Platform, Reiterates Buy Rating - Finviz
H.C. Wainwright Sees Strength in Halozyme Therapeutics’ ENHANZE Platform, Reiterates Buy Rating - Yahoo Finance
HALO Rises Nearly 4% on Strong 2025 Preliminary Data and 2026 Guidance - Finviz
Halozyme stock price target maintained at $58 by Goldman Sachs - Investing.com Canada
Halozyme Acquires Surf Bio for up to $400M - Contract Pharma
H.C. Wainwright reiterates Buy rating on Halozyme stock, maintains $90 price target - Investing.com Canada
Halozyme Therapeutics (NASDAQ:HALO) Updates FY 2026 Earnings Guidance - MarketBeat
Halozyme Therapeutics Inc Azioni (HALO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Halozyme Therapeutics Inc Azioni (HALO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Torley Helen | PRESIDENT AND CEO |
Feb 04 '26 |
Option Exercise |
12.07 |
20,000 |
241,400 |
728,719 |
| Torley Helen | PRESIDENT AND CEO |
Feb 05 '26 |
Option Exercise |
12.07 |
10,000 |
120,700 |
718,719 |
| Torley Helen | PRESIDENT AND CEO |
Feb 04 '26 |
Sale |
77.24 |
20,000 |
1,544,820 |
708,719 |
| Torley Helen | PRESIDENT AND CEO |
Feb 03 '26 |
Sale |
76.12 |
20,000 |
1,522,317 |
708,719 |
| Torley Helen | PRESIDENT AND CEO |
Feb 05 '26 |
Sale |
78.64 |
10,000 |
786,366 |
708,719 |
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):